Glucagon-like peptide-1 (GLP-1)

Overview

Glucagon-like peptide-1 (GLP-1) is a peptide hormone with important roles in glucose homeostasis and energy balance. It is produced primarily by enteroendocrine L-cells in the intestine and acts as an incretin, meaning it enhances glucose-dependent insulin secretion after nutrient intake. In biomedical research and therapeutics, GLP-1 is widely studied for its metabolic effects, including regulation of insulin secretion, appetite, and glycemic control in type 2 diabetes.

A key feature of GLP-1 biology is its rapid inactivation by Dipeptidyl peptidase 4 (DPP-4) (DPP4), which limits its circulating activity. Because of this, many studies focus on either increasing endogenous GLP-1 secretion or preventing its degradation. GLP-1 is therefore relevant not only as a hormone but also as a therapeutic target and biomarker in metabolic disease, obesity, and related cardiometabolic conditions.

Recent Publications Summary

Recent research has explored diverse therapeutic strategies targeting GLP-1 signaling across metabolic, gastrointestinal, and cardiovascular disease contexts. Computational peptide design approaches have generated single-molecule agonists with triple-receptor activity simultaneously engaging GLP-1R, the glucagon receptor (GCGR), and the glucose-dependent insulinotropic polypeptide receptor (GIPR), with molecular modeling predictions indicating balanced, favorable binding profiles for all three receptors compared to endogenous and reference peptides 42530676Jul. These multi-receptor agonists are aimed at optimizing blood glucose control and weight loss outcomes in diabetes and obesity 42530676Jul.

Clinical observations of GLP-1-based therapy have documented measurable effects on gastrointestinal transit physiology. Patients receiving GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists showed significantly prolonged small-bowel transit time compared to non-exposed controls (median 311.0 vs. 236.0 minutes; p<0.001) during capsule endoscopy examination, though gastric transit time remained unaffected 42457308Jul. GLP-1-based treatments are also emerging as adjunctive therapies to bariatric surgery for managing obesity and suboptimal weight loss 42174245May.

Dietary and microbial interventions have been shown to enhance endogenous GLP-1 secretion as a therapeutic strategy. Apple pomace and whole apple fractions increased GLP-1 secretion by 50% in gastric-phase digesta and up to 179% in intestinal-phase digesta relative to glucose controls 41775012Mar, suggesting that polyphenol-rich pomace intake may attenuate postprandial glycemia through GLP-1-dependent mechanisms 41775012Mar. Similarly, Dendrobium huoshanense polysaccharides promoted GLP-1 secretion to exert protective anti-inflammatory effects in a murine ulcerative colitis model via the GLP-1/GLP-1R signaling axis 41962608Apr, while GLP-1 modulation has been identified as a therapeutic target in impaired glucose tolerance 41879385Mar.

At the mechanistic level, the cardioprotective effects of GLP-1 can be compromised by dysbiotic alterations in gut microbiota composition. The bacterium Bacteroides acidifaciens produces a bacterial dipeptidyl peptidase 4 enzyme (BaDPP4) that degrades circulating GLP-1 and other cardioprotective peptides in plasma, thereby amplifying myocardial injury during cardiac ischemia/reperfusion; selective pharmacological inhibition of BaDPP4 mitigated cardiac dysfunction in mice, and clinical correlations between B. acidifaciens abundance and cardiac damage markers were observed in acute myocardial infarction patients 41923637Apr. GLP-1 functions as an important metabolic biomarker and regulator in type 2 diabetes mellitus pathophysiology 41940860Apr, with the GLP-1/GLP-1R axis identified as a key signaling pathway through which microbiota-derived metabolites and bioactive dietary polysaccharides exert antidiabetic effects 41850461Mar.

What Changes, What Holds

1. Multi-receptor GLP-1 agonism broadens the therapeutic concept beyond GLP-1 alone
NEW DIRECTION Computational design of single molecules that engage GLP-1R together with GCGR and GIPR extends the GLP-1 story from a single incretin pathway to multi-receptor pharmacology aimed at better glycemic and weight outcomes 42530676Jul. This does not displace the established role of GLP-1 in glucose homeostasis or its therapeutic relevance; it adds a newer strategy for exploiting that biology.

2. GLP-1-based therapy can slow small-bowel transit without clearly altering gastric transit
NEW DIRECTION Clinical physiology now links GLP-1 receptor agonism and dual GIP/GLP-1 agonism to prolonged small-bowel transit, adding a gastrointestinal effect that sits alongside the baseline’s metabolic framing 42457308Jul. Because the Overview does not discuss motility, this is an added role rather than a contradiction. The bariatric-surgery adjunct use also points to expanding clinical deployment in obesity management 42174245May.

3. Endogenous GLP-1 secretion is becoming a target for diet- and microbiome-based intervention
NEW DIRECTION Apple-derived fractions and polysaccharides are being used to push GLP-1 release upward, shifting attention from merely preserving native hormone activity to actively stimulating secretion 41775012Mar41962608Apr. That fits the baseline’s emphasis on GLP-1 as a metabolic mediator, but it adds practical routes to harness it through food components and gut-derived signaling. The impaired-glucose-tolerance work reinforces GLP-1 modulation as a therapeutic lever 41879385Mar.

4. Gut bacteria can destroy circulating GLP-1 and weaken its cardiometabolic protection
NEW DIRECTION A bacterial DPP4 that degrades GLP-1 introduces a microbiome-mediated brake on the hormone’s activity, extending the baseline’s point about rapid inactivation by host DPP-4 into a disease-relevant microbial mechanism 41923637Apr. This does not overturn the established account; it complicates it by showing that GLP-1 loss can be driven outside the host enzyme system and may matter in myocardial injury. The biomarker and antidiabetic-signaling findings reinforce GLP-1’s centrality in type 2 diabetes 41940860Apr41850461Mar.

Overview update candidates: multi-receptor agonist design as an emerging GLP-1-based therapeutic approach; GLP-1-based therapies affect intestinal transit and are being used adjunctively after bariatric surgery; dietary and microbial strategies that increase endogenous GLP-1 secretion; microbiota-derived GLP-1 degradation as a modifier of cardiometabolic effects.